about
Activated Complement Factors as Disease Markers for SepsisComplement mediators: key regulators of airway tissue remodeling in asthmaComplement in monoclonal antibody therapy of cancerThe complement system and adverse pregnancy outcomesThe Complement System and Antibody-Mediated Transplant RejectionTreatment of neuromyelitis optica: state-of-the-art and emerging therapiesMoss-Produced, Glycosylation-Optimized Human Factor H for Therapeutic Application in Complement Disorders.New milestones ahead in complement-targeted therapy.The extracellular adherence protein from Staphylococcus aureus inhibits the classical and lectin pathways of complement by blocking formation of the C3 proconvertaseRole of complement in host-microbe homeostasis of the periodontium.CAWS administration increases the expression of interferon γ and complement factors that lead to severe vasculitis in DBA/2 miceDeletion of the complement C5a receptor alleviates the severity of acute pneumococcal otitis media following influenza A virus infection in mice.Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention.Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape.Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study.Therapeutic control of complement activation at the level of the central component C3.Anti-complement activity of the Ixodes scapularis salivary protein Salp20.Complement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention.Manipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy.SALO, a novel classical pathway complement inhibitor from saliva of the sand fly Lutzomyia longipalpis.Complement in immune and inflammatory disorders: pathophysiological mechanismsComplement in immune and inflammatory disorders: therapeutic interventions.Complement activation in pediatric patients with recurrent acute otitis media.Human C3 glomerulopathy provides unique insights into complement factor H-related protein function.Locally advanced lung cancer: an optimal setting for vaccines and other immunotherapies.New therapeutic and diagnostic opportunities for injured tissue-specific targeting of complement inhibitors and imaging modalities.An Inhibitor of the Alternative Pathway of Complement in Saliva of New World Anopheline Mosquitoes.Rational engineering of a minimized immune inhibitor with unique triple-targeting properties.Mouse genetics and proteomic analyses demonstrate a critical role for complement in a model of DHRD/ML, an inherited macular degeneration.C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in vitro and mouse models of neuromyelitis optica.Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis.Complement inhibition in cancer therapy.Structural basis for the targeting of complement anaphylatoxin C5a using a mixed L-RNA/L-DNA aptamer.Reincarnation of ancient links between coagulation and complement.Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach.The role of complement in neurological and neuropsychiatric diseases.Novel Evasion Mechanisms of the Classical Complement Pathway.Targeting the complement cascade: novel treatments coming down the pike.From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage.The Evolving Landscape for Complement Therapeutics in Rheumatic and Autoimmune Diseases.
P2860
Q26784268-AEBBFCAE-6F6B-4CC3-9399-3C4C868A0163Q26796418-974893AD-57D4-4E28-BE6F-A2B4BFE78D40Q26860800-31FA16F1-1E53-46A8-B85B-20C5143B8B64Q26863600-49EE8823-0EF6-42B2-B228-03AAF2EAC0B8Q28087773-E0B30F59-0DA6-48C4-AD27-B5A4C27D91BAQ28245749-CCCD4E8D-5620-4D7B-8368-69DFA510A677Q33437488-81E007FB-5FFE-4DFD-B433-01482B1BECB5Q33602320-C8A0E8F4-DDDB-4C24-A123-88BBB330161DQ34647356-2AF8AEE7-2538-4440-938A-2EFFACAB59FEQ34727808-2C439424-7A74-4846-BDEC-D039B51990A0Q34996303-754D6706-D017-4F22-8ACB-9350FC266FBBQ35150544-3A7EA939-5464-456F-87D7-D7C844F675E2Q35236103-DD1C25B3-AE8F-4B44-B2DB-92C8CD3AEF47Q35252156-0B5E2B80-6CB7-4C38-A23A-A91D200668EAQ36170691-15ADCCEE-930C-4E7E-B441-EA9669CCC03FQ36363005-5FE1C135-6ADF-4DAC-8290-5F109C9DD100Q36422019-FB10AA57-C5E5-4CFA-8F4B-2234E90FF42AQ36460034-E1C3EECB-8322-4DDF-B44A-99446626984CQ36463266-F91FC179-4546-4812-9CB5-050B7FA2A3F3Q36497814-A1C2D57F-1E24-4748-9E4E-6444DB761BABQ36756850-3A77F898-9FFD-4823-8E12-538C081A7EBBQ36756854-7EFA1207-C4AD-48AF-812F-9C75F165CFB5Q36864316-FD3DE150-F3DB-4024-B3BF-8C89B8020252Q36890935-27100C80-A046-4C1E-AA5D-90B319DF4EE4Q36946100-554232AE-2996-40E1-AADA-FF276D3617D6Q37180522-E8E3A705-BF5E-4BDF-AB65-F93A31CA8229Q37185654-E45C87FC-0CCC-45DD-8BF5-5E38FE716A4EQ37300691-3BAAADDF-98D2-4CFF-960A-0337D4EFCBF2Q37380159-DA768E74-B59C-4C7C-BC55-816793E51032Q37615906-D74DB740-EC12-497E-A5D4-9299B0617101Q38042223-B1A4EA71-8040-4B58-8559-6AACA60178CEQ38109340-2AB7C1EC-8BBD-4853-AD63-FD6F1B4BDD1FQ38299564-3C645560-9E0F-4616-B263-360281BDAD56Q38543278-94CEB92D-343C-4364-9BEA-3277B3B2852CQ38549182-3BE92048-CC7D-47FC-96AC-4112604540B0Q38590250-A3576A29-E6E0-45CB-BE2E-886C221A68C8Q38824720-DBAF7F85-B0A8-462A-AB53-8E3836B287E6Q38850489-F0D04BB8-3116-4771-B18E-BF48C4331276Q38879877-F1A19839-0256-4A0F-9502-BAEC678E45EDQ39450682-CCAADDB2-8E53-45E3-BC96-6696BBDAB5EE
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Progress and Trends in Complement Therapeutics
@ast
Progress and Trends in Complement Therapeutics
@en
type
label
Progress and Trends in Complement Therapeutics
@ast
Progress and Trends in Complement Therapeutics
@en
prefLabel
Progress and Trends in Complement Therapeutics
@ast
Progress and Trends in Complement Therapeutics
@en
P2860
P1476
Progress and trends in complement therapeutics
@en
P2093
Daniel Ricklin
P2860
P356
10.1007/978-1-4614-4118-2_1
P407
P577
2013-01-01T00:00:00Z